Scholar Rock’s (SRRK) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Scholar Rock (NASDAQ:SRRK) in a research note published on Tuesday morning,RTT News reports. They currently have a $50.00 price objective on the stock.

A number of other research analysts also recently weighed in on the stock. Truist Financial increased their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. HC Wainwright increased their price objective on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.86.

Scholar Rock Trading Up 3.7 %

NASDAQ SRRK opened at $33.36 on Tuesday. The business’s fifty day moving average is $37.94 and its 200-day moving average is $32.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of -14.20 and a beta of 0.59. Scholar Rock has a one year low of $6.76 and a one year high of $46.98.

Insider Buying and Selling

In other news, insider Jing L. Marantz sold 5,655 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the transaction, the insider now owns 67,200 shares of the company’s stock, valued at approximately $2,970,240. The trade was a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tracey Sacco sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the sale, the insider now directly owns 71,750 shares in the company, valued at $2,373,490. This represents a 8.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 299,772 shares of company stock valued at $11,245,798. Company insiders own 19.20% of the company’s stock.

Hedge Funds Weigh In On Scholar Rock

A number of institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after acquiring an additional 269 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Scholar Rock by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after purchasing an additional 379 shares in the last quarter. Amalgamated Bank increased its position in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after purchasing an additional 620 shares during the last quarter. Global Retirement Partners LLC raised its holdings in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after buying an additional 1,031 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.